FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies von Subbiah, V., Iannotti, N.O., Gutierrez, M., Smith, D.C., Féliz, L., Lihou, C.F., Tian, C., Silverman, I.M., Ji, T., Saleh, M.

Volltext

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) von Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Féliz, L., Abou-Alfa, G.K.

Volltext

LBA40 - FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) von Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Féliz, L., Abou-Alfa, G.K.

Volltext

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 von Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Veronese, M.L., Abou-Alfa, G.K.

Volltext